(EMAILWIRE.COM, November 21, 2018 ) Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) pipeline Target constitutes close to 30 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Lysine Specific Histone Demethylase 1A-Pipeline Review, H2 2018, outlays comprehensive information on the Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)-Lysine-specific histone demethylase 1A (KDM1A) also known as lysine (K)-specific demethylase 1A (LSD1) is a protein in encoded by the KDM1A gene. LSD1 specifically demethylates mono-or dimethylated dimethylated histone H3 lysine4 (H3K4) and H3 lysine 9 (H3K9) via a redox process. LSD1 played an important role in a broad spectrum of biological processes, including cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development.
Download sample copy of this Report: http://www.reportsweb.com/inquiry&RW00012283731/sample
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 4 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Central Nervous System, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Small-Cell Lung Cancer, Ewing Sarcoma, Myelodysplastic Syndrome, Sickle Cell Disease, Alzheimer’s Disease, Breast Cancer, Melanoma, Orphan Diseases (Rare Diseases), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Promyelocytic Leukemia, Autoimmune Disorders, Dementia, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Huntington Disease, Leukemias, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Myelofibrosis, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, Obesity, Ovarian Cancer, Parkinson’s Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psychosis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Solid Tumor, Type 2 Diabetes and Viral Infections.
Furthermore, this report also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Get More Information about this Report: http://www.reportsweb.com/inquiry&RW00012283731/buying
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
